Across TCGA pan-cancer cohorts, NPEPL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NPEPL1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NPEPL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPEPL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where NPEPL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.604	0.865	<.001	19	view →
LUAD	DFS	Median	III,IV	0.587	0.897	.011	11	view →
PDAC	DFS	Quartile	All	0.529	0.314	.016	9	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	6	view →
OV	DFS	Median	All	0.609	0.964	.039	4	view →
GBM	OS	Median	All	0.918	0.792	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: NPEPL1 tumor-vs-normal RNA expression · all NPEPL1 data types